{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Surrozen, Inc."},"Symbol":{"label":"Symbol","value":"SRZNW"},"Address":{"label":"Address","value":"171 OYSTER POINT BOULEVARD,SUITE 400, SOUTH SAN FRANCISCO, California, 94080, United States"},"Phone":{"label":"Phone","value":"+1 650 489-9000"},"Industry":{"label":"Industry","value":"Biotechnology: Biological Products (No Diagnostic Substances)"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Surrozen Inc is a class of therapeutics to treat serious diseases characterized by tissue injury. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), and SZN-043 (E3/ASGR1, SWEETS)."},"CompanyUrl":{"label":"Company Url","value":"https://www.surrozen.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Charles Williams","title":"Secretary, Chief Operating & Financial Officer"},{"name":"Craig C. Parker","title":"President, Chief Executive Officer & Director"},{"name":"Li Yang","title":"Executive Vice President-Research"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}